|
|
Article: Nektar Reports that New Data on Exubera Showed Sustained Blood Glucose Control and Pulmonary Function in Patients With Type 2 Diabetes.
- Article from:
- Business Wire
- Article date:
- September 7, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN CARLOS, Calif. -- Nektar Therapeutics (Nasdaq:NKTR) reported today that Pfizer and Aventis announced that new data showed that Exubera(R) (inhaled insulin) was effective and well tolerated in controlling blood glucose levels over a two-year period in patients with Type 2 diabetes. The results were presented today at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany. Nektar develops and provides the inhalers and the powdered insulin for the Exubera(R) product.
These combined results are from two six-month clinical studies in patients with type 2 diabetes that were designed to assess the efficacy of Exubera(R) ...